CSL BEHRING
LIVE

Serial Number

88675262

Owner

CSL Behring LLC

Attorney

Scott D. Woldow

Filing Date

Oct 31, 2019

Add to watchlist:

No watchlists yet
View on USPTO

CSL BEHRING Trademark

Serial Number: 88675262 • Registration: 6655943

CSL BEHRING is a trademark filed by CSL Behring LLC on October 31, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 16 (Paper Goods), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

CSL Behring LLC (13 trademarks)

1020 First Avenue
King of Prussia, PA 194060901

Entity Type: 16

Trademark Details

Filing Date

October 31, 2019

Registration Date

March 1, 2022

Published for Opposition

December 14, 2021

Goods & Services

Education services, namely, providing classes, seminars, and workshops in the field of continuing medical education and health education; Educational services, namely, providing online instruction in the field of health, medicine, pharmaceuticals and medical treatment via an online website; Electronic publications, namely, newsletters in the field of health, medicine, pharmaceuticals and treatment

Treatment of biological products, namely, custom manufacturing and fractionation of blood; Processing of human blood plasma, namely, removing whole blood and separating red blood cells from plasma; treatment of biological products, namely, custom manufacturing and fractionation of blood; production of reagents for immunohaematology laboratories for scientific or medical research use; processing of human blood plasma, namely, removing whole blood and separating red blood cells from plasma; treatment of human blood and plasma; custom manufacturing of human blood and plasma

Electronic publications, namely, newsletters and manuals featuring medical information and health treatment information recorded on computer media; Downloadable educational course materials in the field of health and medical treatment

Pharmaceutical preparations for blood diseases, illnesses and conditions; Pharmaceutical preparations for the treatment or prevention of blood and bleeding disorders; diagnostic preparation for medicinal purposes

Printed matter, namely, printed periodicals, newsletters, and brochures all in the fields of health, medicine and pharmaceuticals; publications, namely, hand-outs in the fields of health, medicine, treatment and pharmaceuticals; Printed instructional, educational, and teaching materials in the field of health, medicine, pharmaceuticals and treatment; Informational flyers featuring health, medicine, pharmaceuticals and treatment information; Brochures about health, medicine, pharmaceuticals and treatment; Pamphlets in the field of health, medicine, pharmaceuticals and treatment information; posters; instruction sheets in the field of health, medicine, pharmaceuticals and treatment; Printed instructional, educational, and teaching materials in the field of health, medicine, pharmaceuticals and treatment

Provision of information relating to wholesale and retail services in the pharmaceutical industry; Provision of information relating to promotion services in the field of promoting awareness of blood diseases, illnesses and conditions and treatment or prevention of blood and bleeding disorders, and promoting awareness of pharmaceutical and health treatments

Medical information services; health care information services; medical diagnostic testing, monitoring and reporting services; patient support services, namely, providing information to patients in the field of administering medications; medical information concerning pharmaceuticals, medical products and blood products; Medical testing for diagnostic or treatment purposes; medical testing of human blood plasma; collection, processing and testing of human blood and plasma for medical purposes

Apparatus of blood analysis; blood testing apparatus

Scientific and technological research, namely, scientific testing and screening services, testing of human blood plasma for safety and quality; research and development of scientific, medical, pharmaceutical and blood products; Product research and development services; Laboratory analysis, namely, medical laboratory services and scientific laboratory services; Laboratory research services relating to pharmaceuticals; management of scientific research projects, namely, conducting scientific research; Pharmaceutical research services; scientific testing and screening services, namely, testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma

Filing History

REGISTERED-PRINCIPAL REGISTER
Mar 1, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 14, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 14, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 24, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 5, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 3, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 3, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 3, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 3, 2021 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 3, 2021 GNRN
NON-FINAL ACTION E-MAILED
Nov 3, 2021 GNRT
NON-FINAL ACTION WRITTEN
Nov 3, 2021 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Oct 1, 2021 ZZZX
WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
Oct 1, 2021 PBMR
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 27, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 27, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 27, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 20, 2021 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
May 13, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
May 13, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
May 13, 2021 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 13, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 13, 2020 GNSL
SUSPENSION LETTER WRITTEN
Oct 13, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 8, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 8, 2020 CRFA
ASSIGNED TO LIE
Sep 3, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 13, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 13, 2020 GNRN
NON-FINAL ACTION E-MAILED
Feb 13, 2020 GNRT
NON-FINAL ACTION WRITTEN
Feb 13, 2020 CNRT
ASSIGNED TO EXAMINER
Feb 5, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 5, 2019 NWOS
NEW APPLICATION ENTERED
Nov 4, 2019 NWAP